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The RIPID project
RIPID (Registro Italiano Pneumopatie Infiltra-
tive Diffuse, or the Italian Register for Diffuse In-
filtrative Lung Disorders) was effectively estab-
lished in 1998 as a joint project of the three major
Italian scientific societies for Respiratory Medi-
cine, AIPO (Associazione Italiana Pneumologi
Ospedalieri, or the Italian Association of Hospital
Specialists in Respiratory Medicine), SIMeR (So-
cietà Italiana di Medicina Respiratoria, or the Ital-
ian Society for Respiratory Medicine), and the Ital-
ian Chapter of WASOG (World Association on
Sarcoidosis and Other Granulomatous Disorders),
who agreed on the need to have a common project
and a single Italian Register, following parallel
projects in other European countries [1–4].
The aim of the RIPID project is tocollect cases
of diffuse infiltrative lung disorders (also known
as interstitial lung disease), diagnosed in different
settings (both in-hospital and out-patient), com-
plete with the information requested in the data
collection form published in the main national
journals of Respiratory Medicine (Medicina
Toracica and Rassegna di Patologia dell’Apparato
Respiratorio) and now available also on-line.
The intention of its promoters and contributors is
to exploit RIPID for research studies, not only in the
epidemiological but also in the clinical and therapeu-
tic fields. In the meantime a series of educational ac-
tivities (courses, seminars, articles) has been planned
to improve knowledge on diffuse infiltrative lung dis-
orders and advertise the project in order that new Cen-
ters may become involved in the collection of data.
To this end, a new internet web site on RIPID
was activated in December 2000 (www.pneumon-
et.it/ripid), allowing prompt access to all informa-
tion concerning the project (aim, programmes,
meetings), to scientific material on diffuse infiltra-
tive lung disorders and to an electronic, updated
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RIPID was established in 1998 as a joint project of the
major Italian scientific societies for Respiratory Medicine,
with the aim to create an Italian Register on diffuse infil-
trative lung disorders that can provide the basis for epi-
demiological and clinical studies of adequate sample size.
In the period from May 1998 to December 2000, 1,382
cases were submitted from 54 Centers in 15 regions of Italy,
54.2% males (mean age ± SD 50.5 ± 16.8 years) and 45.8%
females (50.2 ± 15.3 years). A current smoking habit emerges
in 18% of subjects; former smokers and never-smokers rep-
resent 26% and 56% of the total case series, respectively. The
most frequent disease registered is idiopathic pulmonary fi-
brosis (37.6%), followed in decreasing order by sarcoidosis
(29.2%), and Langherans’ cell hystiocytosis (6.6%). High
resolution computed tomography (HRCT) was considered as
the most important tool for final diagnosis in the majority of
cases (74.4%); 39.4% of patients underwent transbronchial
biopsies, 39.2% bronchoalveolar lavage (BAL). A surgical
biopsy was performed in 20.5% of patients.
A web site has been activated from December 2000
(www.pneumonet.it/ripid), allowing prompt access to all
information and scientific material concerning the project
and to an electronic form for data collection that can be
completed on-line.
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form for data collection that can be completed on-
line. The scientific societies involved in the project
have also undertaken a campaign to diffuse the ini-
tiative at grass-roots level, by circulating letters
among their own members, publishing information
material in their scientific journals and organizing
symposia at national meetings.
The present report refers to the period of
RIPID’s activity from May 1998 to December
2000. Data are those limited to the cases submitted
by fax, using the first version of the data collection
form. The collection of cases was in this period
both retrospective and prospective; since January
2001, inclusion has been exclusively prospective
and will be the object of a second report.
Data collection
The recruitment of cases has followed a regular
linear trend since it started in May 1998. Up to De-
cember 31, 2000, submission of forms was exclu-
sively via fax, with 1,382 cases included in the reg-
istry. Fifty-four Centers in 15 regions of Italy par-
ticipated (figure 1). Most cases (787, 57%) were
submitted from the region of Lombardia, followed
by Emilia Romagna with 186 patients (13%). The
most frequent disease registered is idiopathic pul-
monary fibrosis (IPF), followed in decreasing order
by sarcoidosis, and Langherans’ cell hystiocytosis
(LCH) (table 1); these three disorders account for
more than two-thirds of the total number of cases.
Also represented are a number of very infrequent
lung disorders, that individual specialists rarely
have the occasion to encounter more than once in
their career. For these rare diseases, a national reg-
ister can represent an extremely important tool for
a systematic study and deeper knowledge.
Socio-demographic characteristics
Male sex is slightly more represented than fe-
male (54.2% vs 45.8%); mean age (± SD) is 50.5
years (± 16.8) for males and 50.2 years (± 15.3) for
females. A current smoking habit emerges in 18%
of subjects; former smokers and never-smokers
represent 26% and 56% of the total case series, re-
spectively. The analysis of smoking habits correct-
ed by disease and sex demonstrates, as expected,
that most smoker/ex-smoker patients, in both sex-
es, belong to the LCH group.
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Fig. 1. – Case series divided according to the Region where patients were recruited (only cases registered up to December 2000 with the first
version of the data form).
Clinical features
The number of symptoms at the onset of the
disease was 1 in 39.4%, 2 in 37.8% and 3 in 15.6%
of cases; in 7.3% of subjects no symptoms were re-
ported. Eighty percent of asymptomatic cases with
occasional diagnosis were represented by pul-
monary sarcoidosis. Symptom prevalence is re-
ported in figure 2; “other” refers to several differ-
ent symptoms, mainly extrapulmonary. In 33 pa-
tients presentation of the disease was pneumotho-
rax; of these, 45% were affected by histiocytosis X
and 48% by lymphangioleiomyomatosis. Percent
distribution of symptoms at onset for the main dis-
orders is shown in table 2; dyspnea is the most fre-
quent symptom at onset for numerous diseases,
such as pulmonary fibrosis, extrinsic allergic alve-
olitis (hypersensitivity pneumonitis), and drug-in-
duced lung disorders. It is interesting to note that
extra-pulmonary symptoms were common at the
onset of sarcoidosis (mainly erythema nodosum),
histiocytosis X and lymphangioleiomyomathosis.
Respiratory function data were in the normal
range in 39.9% of cases; a restriction pattern was
found in 43.4%, an obstruction pattern in 9.7% and
a mixed pattern in 7.1% of patients. At the time of
inclusion in the Register respiratory function was
normal in most cases of sarcoidosis, Wegener’s
syndrome, and pulmonary lymphoma; an obstruc-
tive pattern was found to be quite characteristic for
lymphangioleiomyomatosis and obstructive bron-
chiolitis. Restriction was typical for pulmonary fi-
brosis, alveolar proteinosis and drug-induced lung
disease.
Diagnostic procedures
An analysis of the individual diagnostic proce-
dures shows that chest high resolution computed
tomography (HRCT) was considered as the most
important tool for final diagnosis in the majority of
cases (74.4%); 39.4% of patients underwent trans-
bronchial biopsies, 39.2% bronchoalveolar lavage
(BAL). A surgical biopsy was performed in 20.5%
of patients, of whom 62.8% by thoracotomy,
31.7% by videothoracoscopy (VATS) and 5.5% by
thoracoscopy. Interestingly, the use of VATS
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Table 1. – Cases enrolled according to type of pathology*
% No
Idiopathic pulmonary fibrosis 37,6 520
Sarcoidosis 29,2 403
Langerhans’ cell Hystiocytosis 6,6 91
BOOP 5,0 69
Extrinsic allergic alveolitis 3,7 51
Lymphangioleiomyomatosis 2,5 35
Eosinophilic pneumonia 1,9 26
Drug-induced lung disease 1,7 23
Wegener syndrome 1,3 18
Alveolar proteinosis 1,1 15
Constrictive bronchiolitis 0,8 11
Hamman-Rich syndrome 0,8 11
MALT pulmonary lymphoma 0,6 8
Diffuse alveolar haemorrhage 0,5 7
Lymphomatoid granulomatosis 0,5 7
Other diagnosis 6,2 85
* Data here reported are limited to the cases submitted up
to December 31 2000, by fax, using the first version of the
data collection form.
BOOP = bronchiolitis obliterans organizing pneumonia;
MALT = mucosa associated lymphoid tissue.
Fig. 2. – Symptoms at onset in order of frequency.
showed a significant increase during the year 2000
(17%), as compared to an average use in 6% of
cases in the six years prior. On the contrary, over
the same period the use of HRCT (in 72% of cas-
es on average) remained fairly constant.
Table 3 shows the number and percentage of
cases in whom diagnosis was supported by a com-
bination of investigative tools; the first ten account
for 80% of all combinations employed. Reporting
data for the individual disorders (see table 4), the
most represented diagnostic combination in almost
all cases (excepting only obliterative bronchiolitis
and extrinsic allergic alveolitis) involves only ra-
diological investigations.
Conclusions
This preliminary report on RIPID activities
makes the point that it is a joint project of the ma-
jor Italian scientific societies for Respiratory Med-
icine in the field of diffuse infiltrative lung disor-
ders, with the aim to create an Italian Register(fol-
lowing the example of scientific societies in other
European countries) that can provide the basis for
designing epidemiological and clinical studies of
adequate sample size. Collateral activities have
been implemented in the course of the project,
such as joint seminars with pathologists and radi-
ologists in accordance with the respective national
scientific societies. These joint seminars represent
a very profitable forum for the interdisciplinary
discussion of case reports. Other important activi-
ties are represented by the different sections of the
RIPID website, i.e. the possibility for debate, edu-
cation, newsgroups, on-line consultation, on-line
publication of scientific material and general in-
formation, and real time update of statistics fol-
lowing on-line input of new cases.
The Scientific Committee and the promoting
scientific societies are confident that the RIPID
Register can represent a “lab” to test new forms of
scientific research based on cooperation among
specialists with a common interest in a field of
Respiratory Medicine, i.e. diffuse infiltrative lung
disorders, that, without such joint collaboration,
could risk neglect with, as the inevitable conse-
quence, inadequate standards of patient manage-
ment.
367
ITALIAN REGISTER FOR DIFFUSE INFILTRATIVE LUNG DISORDERS (RIPID)
Table 2. – First symptom at presentation in the individual disorders
cases DYSPNEA COUGH FEVER OTHER MD*
no. % % % % %
Idiopathic Pulmonary Fibrosis 520 63.5 22.5 3.5 6.9 3.7
Sarcoidosis 403 29.5 18.6 4.2 35.5 12.2
Langerhans’ cell Hystiocytosis 91 26.4 26.4 5.5 34.1 7.7
Other Disorders 85 54.1 16.5 7.1 17.6 4.7
BOOP 69 30.4 14.5 37.7 10.1 7.2
Extrinsic Allergic Alveolitis 51 39.2 33.3 13.7 3.9 9.8
Lymphangioleiomyomatosis 35 31.4 8.6 0.0 51.4 8.6
Eosinophilic Pneumonia 26 26.9 30.8 30.8 11.5 0.0
Drug Induced Lung Disease 23 39.1 21.7 13.0 8.7 17.4
Wegener Syndrome 18 22.2 0.0 22.2 55.6 0.0
* = Missing data.
Table 3. – Combination of diagnostic procedures used
No. %
Clinical examination + standard chest X-ray + HRCT 282 20.4
Clinical examination + standard chest X-ray + HRCT + BAL + transbronchial biopsy 176 12.7
Clinical examination + standard chest X-ray + HRCT + transbronchial biopsy 147 10.6
Clinical examination + standard chest X-ray 100 7.2
Clinical examination + standard chest X-ray + HRCT + BAL 139 10.1
Clinical examination + standard chest X-ray + HRCT + thoracotomy 59 4.3
Clinical examination + standard chest X-ray + transbronchial biopsy 56 4.1
Missing data 47 3.4
Clinical examination + standard chest X-ray + transbronchial biopsy + BAL 55 4.0
Clinical examination + standard chest X-ray + BAL 56 4.1
Other combinations 265 19.2
HRCT = high resolution computed tomography; BAL = bronchoalveolar lavage.
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Table 4. – Combination of the diagnostic investigations for the individual disorders
A B C N°
Idiopathic Pulmonary Fibrosis 130 61 61 520
Sarcoidosis 68 33 49 403
Other disorders 23 7 12 85
Langerhans’ cell Hystiocytosis 19 3 14 91
BOOP 8 16 10 69
Extrinsic Allergic Alveolitis 4 8 9 51
Lymphangioleiomyomatosis 9 3 4 35
Eosinophilic Pneumonia 4 5 4 26
Drug-induced lung disease 6 3 23
Wegener Syndrome 4 5 4 18
Constrictive Bronchiolitis 1 1 1 15
Alveolar Proteinosis 1 11
MALT Pulmonary Lymphoma 2 1 11
Diffuse Alveolar Haemorrhage 1 2 2 8
Hamman-Rich Syndrome 1 1 7
Lymphomatoid Granulomatosis 7
Missing Data 1 1 3 2
Total 282 147 176 1382
A: Clinical examination + standard chest X-ray + HRCT
B: Clinical examination + standard chest X-ray + HRCT + transbronchial biopsy
C: Clinical examination + standard chest X-ray + HRCT + BAL + transbronchial biopsy.
BOOP = bronchiolitis obliterans organizing pneumonia; MALT = mucosa associated lymphoid tissue; HRCT = high
resolution computed tomography; BAL = bronchoalveolar lavage.
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